Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has history of varicella or residence in a VZV-endemic area for ≥30 years~* Is male, female not of reproductive potential, or female of reproductive potential and has a negative pregnancy test and agrees to avoid becoming pregnant throughout the study~Exclusion Criteria:~* Has history of hypersensitivity to any vaccine component~* Has previously received any varicella or zoster vaccine~* Has received an influenza vaccine for the 2015-16 season~* Has history of Herpes zoster~* Has received immunoglobulin, monoclonal antibodies, or any blood products within 5 months before study vaccination~* Is pregnant or breastfeeding, or expecting to conceive during the study~* Has used immunosuppressant therapy~* Has known or suspected immune dysfunction~* Has experienced Guillain-Barré syndrome within 6 weeks~* Has severe thrombocytopenia or any other coagulation disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Concomitant Vaccination (Type: EXPERIMENTAL): ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
- Nonconcomitant Vaccination (Type: EXPERIMENTAL): Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4

Based on this trial design, predict the completion outcome and termination type (if applicable).